The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.50
Bid: 8.40
Ask: 8.60
Change: 0.30 (3.66%)
Spread: 0.20 (2.381%)
Open: 8.40
High: 8.55
Low: 8.40
Prev. Close: 8.20
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Company Update: SuperMeat

7 Sep 2023 07:00

RNS Number : 6321L
Agronomics Limited
07 September 2023
 

07 September 2023

Agronomics Limited

("Agronomics" or the "Company")

Portfolio Company SuperMeat Meets Kosher Standards for Its Cultivated Chicken

 

Agronomics (ANIC:LSE), the leading listed company focused on the field of cellular agriculture, is pleased to announce that its portfolio company, SuperMeat The Essence of Meat Ltd ("SuperMeat"), has met Kosher standards for its chicken cell line.

This represents a historic milestone for the industry being the first time that cultivated poultry has been recognised as meeting Kosher, under the stringent Mehadrin standards. OU Kosher, the Kosher certification division of the Orthodox Union ("OU") determined that SuperMeat's product met the necessary standards. The OU oversees the kosher certification of over 1.3 million products and over 14,000 facilities in 104 countries.

Following this recognition, the parties involved are embarking on a thorough examination of the entire supply chain and the cultivated meat production process, thereby establishing clear guidelines for other enterprises in the cultivated meat sector. This endeavour is expected to initiate a Kosher meat certification process for the entire industry and is a pivotal moment in the overlap of religious dietary standards and advanced food technology in the cultivated meat industry.

Agronomics has invested a total of US$ 12.5 million to date and has equity ownership of 7.8% in SuperMeat on a fully diluted basis which, subject to audit, represents 9.3% of the last published Net Asset Value of the Company (30.06.23) including post-balance sheet adjustments.

The OU's recognition came after a series of in-depth discussions and scientific reviews. These reviews focused on avian embryogenesis and stem cells, including the observation of the excision of embryonic stem cells from a fertilised chicken egg.

 

Rabbi Menachem Genack, CEO of OU Kosher and Rabbi of Congregation Shomrei Emunah, author and teacher at Yeshiva University, stated:

"The kosher certification for cultivated meat poses a unique halachic challenge, requiring innovative guidelines that mirror the scientific and technological advancements integral to these novel products. This collaboration aims to bridge the gap between scientific understanding and halachic adjudication, setting unprecedented standards in the cultivated meat industry."

Jim Mellon, Co-Founder and Executive Director of Agronomics, commented:

"We are delighted that our portfolio company, SuperMeat, is paving the way for cultivated meat products to achieve kosher certification. This demonstrates the cutting-edge nature of SuperMeat's technology, as well as Agronomic's ability to identify the leading innovators in cultivated agriculture. This development opens up a considerable global market opportunity, with an estimated $11bn a year being spent on kosher foods in the US alone. It is also another major step forward for the industry toward broad regulatory approval following FDA assent issued earlier this year."

Ido Savir, CEO of SuperMeat, stated:

"Aligning our technology with kosher dietary laws holds immense significance for us. This step represents our commitment to inclusivity and respect for diverse dietary needs, making our cultivated chicken meat accessible to audiences around the world. This recognition of our process is a testament to our meticulous attention to detail and the high standards we uphold. We believe this historic initiative with the Orthodox Union not only broadens the options for Kosher consumers worldwide but will also set clear guidelines for other companies in the cultivated meat industry seeking Kosher certification, opening new avenues for the Kosher food industry."

 

For more information, please contact press@supermeat.com.

 

About Orthodox Union

The Orthodox Union is one of the largest Orthodox Jewish organisations in the United States. Founded in 1898, the OU supports a network of synagogues, youth programs, Jewish and Religious Zionist advocacy programs, programs for the disabled, localised religious study programs, and international units. Its OU Kosher division is the world's largest and most widely recognised kosher certification agency. OU Kosher maintains a kosher certification service, whose circled-U hechsher symbol - Ⓤ - is found on the labels of up to 70% of kosher commercial and consumer food products. For more information, please visit https://www.ou.org/.

 

About SuperMeat

SuperMeat is a food-tech company working to supply the world with high-quality meat grown directly from animal cells. The company's products offer a delicious meat experience and a high-quality nutritional profile while being manufactured in a sustainable, GMO-free, and slaughter-free way. SuperMeat's proprietary cultivated meat platform allows food companies to be at the forefront of the emerging cultivated meat industry and manufacture a wide range of products containing cultivated meat inside. SuperMeat is the first B2B company to address the entire poultry meat category from fat to muscle, providing a complete solution to cultivated meat production. For more information, please visit https://supermeat.com/.

 

About Agronomics

Agronomics is the leading listed venture capital firm with a focus on cellular agriculture. The Company has established a portfolio of over 20 companies at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population.

 

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

 

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists' claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5℃.

 

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however, still, less than US$ 5 billion has been invested worldwide since the industry's inception in 2016.

For further information please contact:

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord Genuity Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Bob Huxford

George Esmond

Anthony Hughes

Alice Cho

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFEDALIRIIV
Date   Source Headline
23rd Dec 201612:00 pmRNSFinal Results and Notice of AGM
22nd Dec 20162:41 pmRNSLoan to the Diabetic Boot Company Ltd
12th Oct 20167:00 amRNSNet Asset Value(s)
22nd Jul 20167:00 amRNSNet Asset Value(s)
29th Apr 20167:00 amRNSNet Asset Value calculation to 31 March 2016
15th Apr 20167:00 amRNSChange of Adviser
18th Mar 20167:00 amRNSHolding(s) in Company
17th Mar 20167:00 amRNSInterim Results for the six months to 31 Dec 2015
10th Feb 201612:11 pmRNSResult of AGM
25th Jan 20167:00 amRNSNet Asset Value(s)
22nd Dec 20157:00 amRNSAnnual Audited Results and Notice of AGM
17th Dec 20154:00 pmRNSDBC receives US FDA approval to market PulseFlowDF
4th Nov 20157:00 amRNSNet Asset Value(s)
30th Jul 20157:01 amRNSNet Asset Value(s)
15th Apr 20157:00 amRNSNet Asset Value as at 31 March 2015
30th Mar 20157:00 amRNSInterim results for 6 months to 31 December 2014
6th Feb 201512:21 pmRNSClose of Tender Offer
4th Feb 20155:36 pmRNSRe Results of Tender Offer
2nd Feb 20158:00 amRNSResults of Tender Offer
23rd Jan 20157:00 amRNSHolding(s) in Company
15th Jan 201511:56 amRNSHolding(s) in Company
14th Jan 20157:00 amRNSTender Offer
12th Jan 20159:32 amRNSNet Asset Value
30th Dec 20147:00 amRNSAnnual audited results
23rd Dec 201411:58 amRNSHolding(s) in Company
28th Nov 20142:04 pmRNSTender Offer in respect of Magna Biopharma
21st Oct 20147:00 amRNSNet Asset Value to 30 September 2014
22nd Jul 20147:00 amRNSNet Asset Value(s)
8th Apr 20147:00 amRNSNet Asset Value calculations to 31 March 2014
31st Mar 20147:00 amRNSInterim Results for the six months to 31 Dec 2013
24th Jan 201411:21 amRNSHolding(s) in Company
20th Jan 201410:56 amRNSHolding(s) in Company
17th Jan 20147:00 amRNSNet Asset Value(s)
15th Jan 20147:00 amRNSAppointment of Nominated Adviser
6th Jan 20145:49 pmRNSHolding(s) in Company
20th Nov 20134:04 pmRNSHolding(s) in Company
13th Nov 20135:13 pmRNSHolding(s) in Company
12th Nov 20137:00 amRNSResult of General Meeting
24th Oct 20137:01 amRNSNotice of General Meeting
24th Oct 20137:00 amRNSAnnual Financial Report
18th Oct 201311:23 amRNSHolding(s) in Company
18th Oct 20137:00 amRNSNet Asset Value(s)
4th Oct 20132:13 pmRNSHolding(s) in Company
26th Sep 20135:10 pmRNSHolding(s) in Company
13th Sep 201311:32 amRNSHolding(s) in Company
6th Sep 20135:29 pmRNSHolding(s) in Company
6th Aug 20139:40 amRNSHolding(s) in Company
11th Jul 20137:00 amRNSNet Asset Value(s)
15th Apr 201312:34 pmRNSDirectorate Change
12th Apr 20132:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.